source
- aTyr Pharma cuts 60% of staff to fund second phase 3 trial of lung disease drug efzofitimodaTyr Pharma announced it will reduce its workforce by about 60%, leaving roughly 20 employees, to reallocate resources toward its lung disease program. The cut follows the company's previous phase…
- Regeneron Ventures leads $75 million Series A for eczema-focused antibody startup InfinimmuneInfinimmune, a Bay Area biotech developing antibody therapies for eczema, announced a $75 million Series A financing round. The round was co-led by Regeneron Ventures and Playground Global, with p…